IMRX: Atebimetinib shows 17.3 months median OS in first-line pancreatic cancer with improved tolerability
Phase III trials of atebimetinib in first-line pancreatic cancer are progressing, with strong phase II data showing 17.3 months median OS and improved tolerability. The drug's unique mechanism addresses prior MEK inhibitor limitations and supports future combination strategies with RAS inhibitors.B…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.